Respiratory

Empyema and parapneumonic effusion management

Clinical Overview and When to Suspect Empyema

— Stage 1 (exudative/simple): sterile, free-flowing, pH >7.20, glucose >40, LDH <1000

— Stage 2 (fibrinopurulent/complicated): bacterial invasion, loculations forming, pH <7.20, glucose <40, LDH >1000

— Stage 3 (organizing/empyema): thick pleural peel, frank pus, requires drainage ± decortication

— Pneumonia patient with persistent fever >48–72 hr despite appropriate antibiotics

— New or enlarging pleural effusion on follow-up CXR

— Worsening dyspnea, pleuritic chest pain, leukocytosis that fails to trend down

— Hospitalized patient with anaerobic risk (alcohol use, aspiration, poor dentition, seizure disorder, NG tube)

— Community-acquired: Streptococcus (anginosus/milleri group, pneumoniae), Staph aureus, anaerobes

— Hospital-acquired: MRSA, gram-negatives (Pseudomonas, Klebsiella, E. coli), polymicrobial

— Post-thoracic surgery, esophageal rupture, chest trauma — distinct flora

Board pearl: The single most exam-tested trigger is the CAP patient not defervescing by day 3 with a new effusion — always image and tap. Do not simply broaden antibiotics; you must sample the pleural fluid to risk-stratify. Delayed drainage is the dominant driver of mortality, length of stay, and need for surgical decortication on Step 3 vignettes.

Definition spectrum — parapneumonic effusion (PPE) is any pleural fluid accumulation adjacent to bacterial pneumonia, lung abscess, or bronchiectasis; empyema is frank pus in the pleural space or a positive Gram stain/culture

Three-stage natural history (Light classification):

When to suspect in a Step 3 vignette:

Epidemiology — ~20–40% of hospitalized CAP develop PPE; ~10% progress to complicated/empyema; mortality 10–20%, up to 30% in elderly or immunocompromised

Microbiology shift by setting:

Presentation Patterns and Key History

— Recurrent or persistent fevers, night sweats, rigors

— Pleuritic chest pain localized to one hemithorax

— Productive cough, dyspnea worsening rather than improving

— Anorexia, weight loss, malaise — especially with anaerobic empyema (more indolent, weeks of symptoms)

— Alcohol use disorder, poor dentition/periodontal disease, witnessed aspiration, seizure, stroke with dysphagia, decreased LOC

— Foul-smelling sputum or pleural fluid is pathognomonic for anaerobes

— Slow tempo: 2–4 weeks of low-grade fever and weight loss

— Recent esophageal instrumentation, EGD with dilation, Boerhaave, chest tube, thoracic surgery

— Esophagopleural fistula → polymicrobial empyema with oral flora and Candida

— Prior pneumonia episodes, TB exposure, HIV status, IV drug use

— Travel (TB, paragonimiasis), occupational exposures

— Immunosuppression: chemotherapy, biologics, transplant, diabetes (poor control → klebsiella)

— Anticoagulation status (affects drainage decisions)

Key distinction: A transudate (CHF, cirrhosis, nephrotic syndrome) does not become empyema and rarely needs drainage — but a transudate can become secondarily infected if instrumented, producing a complicated effusion with discordant Light's criteria. Always reassess pretest probability when the clinical picture and fluid biochemistry disagree.

Step 3 management: Ask explicitly about dental hygiene and aspiration risk in any indolent empyema vignette — it directs anaerobic coverage and may prompt dental consult before discharge to prevent recurrence.

Classic subacute presentation — patient treated for pneumonia 5–10 days ago, now returns with:

Acute presentation — severe pneumonia with rapid effusion accumulation, sepsis physiology, often Strep pneumoniae or S. aureus

Anaerobic/aspiration empyema clue set:

Post-procedural/iatrogenic context:

Targeted history questions for Step 3:

Physical Exam Findings and Hemodynamic Assessment

— Decreased tactile fremitus over the effusion (fluid dampens vibration)

— Tracheal deviation away from a massive effusion

— Subcutaneous emphysema if associated bronchopleural fistula or post-thoracostomy

— Diminished or absent breath sounds over effusion

— Egophony (E→A) and bronchial breath sounds at the upper border (compressed lung)

— Pleural friction rub early; absent once fluid accumulates

— Fever, often >38.5°C; rigors suggest bacteremia (~10–15% of empyema)

— Tachycardia, hypotension if septic — apply qSOFA/SIRS criteria

— Clubbing in chronic empyema or underlying bronchiectasis

— MAP <65 despite fluids → septic shock workup, broad antibiotics within 1 hour, lactate

— Hypoxia not corrected with supplemental O2 → consider ARDS, large effusion compromising ventilation

— New AF or RV strain → consider concomitant PE in differential

Board pearl: The exam finding pathognomonic for a large effusion compressing lung is egophony with bronchial breath sounds at the superior margin plus dullness below — this is compressive atelectasis, not consolidation, and resolves with drainage.

CCS pearl: On the CCS interface, order vital signs Q2H initially, lactate, and blood cultures × 2 before antibiotics when sepsis is suspected — moving the clock forward after antibiotics without cultures is a graded misstep.

Inspection — tachypnea, accessory muscle use, asymmetric chest expansion with affected side lagging; cachexia in chronic empyema

Palpation:

Percussion — dullness to flat percussion over the effusion, with classic shifting dullness when patient repositioned (not present once loculated)

Auscultation:

Systemic signs:

Hemodynamic red flags requiring immediate action:

Diagnostic Workup — Initial Labs and Imaging

— CBC with differential — leukocytosis with left shift; lymphopenia hints at TB or viral

— CMP — albumin (for Light's criteria), creatinine, glucose

— LDH (serum, for Light's), CRP, procalcitonin (trends with treatment response)

— Blood cultures ×2 before antibiotics — positive in 10–15%, often S. pneumoniae or S. aureus

— HIV testing, sputum Gram stain and culture, urinary pneumococcal and Legionella antigens

— Coagulation panel before thoracentesis if on anticoagulants (hold per institutional policy; INR <1.5, platelets >50K typical thresholds)

— >200 mL blunts costophrenic angle on PA; >50 mL detectable on lateral

— Lateral decubitus film historically used to assess free-flow (>1 cm layering = tap-able) — largely replaced by ultrasound

— Meniscus sign, loculated D-shaped opacity along chest wall = empyema

— Distinguishes anechoic (simple) vs septated/loculated vs echogenic (exudate/empyema)

— Guides safe thoracentesis site (avoid diaphragm, liver, spleen)

— Reduces pneumothorax risk ~5-fold vs landmark technique

— Split pleura sign (enhancement of thickened visceral and parietal pleura) is the imaging hallmark of empyema

— Identifies loculations, lung abscess, endobronchial obstruction, esophageal pathology

Step 3 management: For any new effusion in a febrile pneumonia patient, the next step is bedside ultrasound and diagnostic thoracentesis if >10 mm thickness on lateral decubitus or US — do not "wait and see" on antibiotics alone. Delay >24 hours is a recurring wrong-answer trap.

Labs:

Chest X-ray (PA and lateral):

Bedside thoracic ultrasound — preferred for all suspected effusions:

CT chest with IV contrast — when ultrasound unclear, planning drainage:

Diagnostic Workup — Pleural Fluid Analysis

— pH (collect anaerobically in heparinized blood gas syringe, on ice, run within 1 hour)

— Glucose, LDH, total protein, cell count with differential

— Gram stain and culture (aerobic + anaerobic bottles, increases yield ~20%)

— Cytology if malignancy possible; AFB smear/culture and ADA if TB suspected

— Amylase (esophageal rupture, pancreatitis-related effusion)

— Triglycerides if milky (chylothorax >110 mg/dL)

— Pleural/serum protein >0.5

— Pleural/serum LDH >0.6

— Pleural LDH >⅔ upper limit of normal serum LDH

— Simple PPE: free-flowing, pH >7.20, glucose >40, negative Gram stain/culture → antibiotics alone, repeat imaging

— Complicated PPE: pH <7.20 OR glucose <40 OR positive Gram stain/culture, loculated → chest tube drainage required

— Empyema: frank pus on aspiration → chest tube + antibiotics ± fibrinolytics ± surgery

— Pleural fluid ADA >40 U/L with lymphocytic predominance → TB pleurisy

— Eosinophilia >10% → blood, air, drugs, malignancy, parasites

— Very low glucose (<30) → empyema, RA, malignancy, TB

Board pearl: The pH threshold of 7.20 is the most exam-tested numerical cutoff for chest tube placement in PPE — memorize it. If pH unavailable, use glucose <40 or positive Gram stain as surrogate. Frank pus on aspiration bypasses the need to wait for pH — drain immediately.

Key distinction: A bloody tap can falsely lower pH; check pleural RBC and recalculate.

Thoracentesis is the definitive diagnostic step — send fluid for:

Light's criteria (exudate if any one met):

Categorizing parapneumonic effusion (ACCP/BTS framework):

Adjunctive markers:

Risk Stratification and Management Logic

— Category 1 (very low risk): minimal free-flowing effusion (<10 mm on lateral decubitus/US), no need to tap → antibiotics alone

— Category 2 (low risk): small-moderate free-flowing (>10 mm to <½ hemithorax), pH ≥7.20, glucose ≥60, negative Gram stain/culture → antibiotics, serial imaging

— Category 3 (moderate risk): large (>½ hemithorax), loculated, thickened parietal pleura, OR pH <7.20, glucose <60, positive Gram stain → chest tube drainage + antibiotics

— Category 4 (high risk): pus → chest tube + antibiotics, low threshold for fibrinolytics or VATS

— Renal (urea), Age, Purulence, Infection source (community vs hospital), Dietary (albumin)

— Score 0–2 low, 3–4 medium, 5–7 high risk → escalate care, early surgical consult

— Stabilize: O2, IV fluids, sepsis bundle if applicable

— Empiric antibiotics within 1 hour of recognition (do not wait for tap if septic, but obtain blood cultures first)

— Thoracentesis with full fluid panel

— Risk-stratify → drainage decision within 24 hours

— Repeat imaging at 24–48 hours to confirm drainage adequacy

Step 3 management: When the vignette gives pH 7.15, glucose 30, and loculated effusion → answer is chest tube placement, not "continue antibiotics and observe." The trap answer is always escalation of antibiotics alone.

CCS pearl: Order pulmonology and thoracic surgery consults early in high-RAPID-score patients; documenting the consult time matters for scoring.

ACCP risk categories integrate anatomy, bacteriology, and chemistry to predict poor outcome:

RAPID score (mortality prediction at 3 months for pleural infection):

Initial management algorithm:

Source control timeline — every hour of delayed drainage in complicated PPE/empyema increases LOS and surgical referral; aim for chest tube within 24 hours of diagnosis when indicated

Pharmacotherapy — Empiric Antibiotic Regimens

— Ampicillin-sulbactam 3 g IV q6h (preferred — anaerobic coverage built in)

— Or ceftriaxone 2 g IV daily + metronidazole 500 mg IV q8h

— Or piperacillin-tazobactam 4.5 g IV q6h if broader gram-negative concern

— Add vancomycin 15–20 mg/kg IV q8–12h (trough 15–20) or linezolid 600 mg IV q12h if MRSA risk (recent hospitalization, IVDU, prior MRSA, severe sepsis)

— Vancomycin + piperacillin-tazobactam (standard)

— Or vancomycin + meropenem 1 g IV q8h if ESBL concern

— Or vancomycin + cefepime 2 g IV q8h + metronidazole

— Broad spectrum + antifungal (fluconazole or echinocandin) if Candida on Gram stain

— Aminoglycosides penetrate pleural space poorly and are inactivated at low pH — avoid as monotherapy

— Most beta-lactams, fluoroquinolones, vancomycin, linezolid achieve adequate pleural levels

— Clindamycin has good anaerobic and pleural penetration but rising Bacteroides resistance limits monotherapy

— Narrow based on culture results at 48–72 hours

— Duration: 2–6 weeks total, guided by clinical response, drainage adequacy, and imaging

— Transition to PO once afebrile 48 hours, drain output minimal, fluid sterile, and patient eating

— Typical regimen: 1–2 weeks IV → amoxicillin-clavulanate 875/125 PO BID or moxifloxacin 400 mg PO daily to complete course

Board pearl: Empiric coverage of anaerobes is mandatory in community-acquired empyema even without obvious aspiration — oral streptococci (e.g., S. anginosus group) frequently co-infect with anaerobes. Ceftriaxone alone is a wrong answer.

Community-acquired empyema — cover strep, anaerobes, MSSA:

Hospital-acquired/healthcare-associated empyema — cover MRSA + Pseudomonas + anaerobes:

Post-thoracic surgery or esophageal source:

Antibiotic pharmacology pearls:

De-escalation and duration:

Procedures — Drainage, Fibrinolytics, and Surgery

— Small-bore catheters (10–14 Fr) image-guided are equivalent to large-bore in most series (MIST-1 data) — preferred for comfort, equal efficacy

— Large-bore (≥24 Fr) reserved for frank pus that won't drain through small catheter

— Connect to water seal with –20 cm H2O suction; flush small catheters with 30 mL saline q6h to prevent occlusion

— Document daily output, character; pull when output <100–150 mL/day, fluid clear, lung re-expanded on imaging

— MIST-2 regimen: tPA 10 mg + DNase 5 mg intrapleurally BID × 3 days

— Reduces surgical referral by ~75%, improves drainage, shortens LOS

— tPA alone or DNase alone are inferior — combination is the standard

— Contraindications: active bleeding, recent stroke, bronchopleural fistula

— Failure of tube drainage + fibrinolytics at 5–7 days

— Persistent sepsis, residual loculated collection, trapped lung with pleural peel

— VATS (video-assisted thoracoscopic surgery) first-line — debridement and decortication

— Open thoracotomy with decortication for chronic empyema (>4–6 weeks) with thick fibrous peel

— Empyema necessitans (extension through chest wall) requires combined surgical and infectious disease management

CCS pearl: Order post-procedure chest X-ray after every tube placement and after each fibrinolytic instillation course to assess re-expansion and rule out pneumothorax.

Step 3 management: Don't jump straight to VATS — fibrinolytics-first is correct unless trapped lung or chronic peel.

Tube thoracostomy — cornerstone of source control:

Intrapleural fibrinolytics — for loculated effusion or inadequate drainage:

Surgical intervention indications:

Sequencing logic: antibiotics → thoracentesis → chest tube → fibrinolytics if loculated/inadequate drainage at 24–48h → VATS if failure at 5–7 days

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher mortality (up to 30%); higher RAPID scores driven by age, urea, albumin

— Often present afebrile with delirium, falls, or failure to thrive instead of classic fever/cough

— Lower threshold for imaging when functional decline follows pneumonia

— Increased risk of drug interactions with warfarin, statins (linezolid-SSRI serotonin syndrome, fluoroquinolone-QT prolongation)

— Goals-of-care discussion early — surgical decortication may not be appropriate; consider palliative drainage

— Vancomycin — dose by weight, target trough or AUC; adjust frequency by CrCl

— Pip-tazo — extend interval to q8h or q12h at CrCl <40; risk of AKI when combined with vancomycin (synergy concern)

— Aminoglycosides — avoid (already poor pleural penetration plus nephrotoxicity)

— Fluoroquinolones — renal dose adjustment for levofloxacin

— Avoid NSAIDs for pleuritic pain in CKD; use acetaminophen + low-dose opioid if needed

— Metronidazole — reduce dose 50% in severe cirrhosis (Child-Pugh C)

— Linezolid — monitor for lactic acidosis, thrombocytopenia (>2 weeks use)

— Avoid clindamycin if possible (hepatotoxicity, C. difficile risk)

— Low albumin → underestimates Light's protein ratio; use serum-pleural albumin gradient <1.2 to confirm exudate

— Hold warfarin, DOACs, heparin before thoracentesis or chest tube; restart when bleeding risk acceptable (typically 24–48 h post-tube, individualized)

— Bridge with prophylactic-dose LMWH if high thrombotic risk (mechanical valve, recent VTE)

Board pearl: Vancomycin + piperacillin-tazobactam synergistic nephrotoxicity — monitor creatinine daily; switch to cefepime + vancomycin if AKI develops.

Step 3 management: Always reassess goals of care in frail elderly empyema patients before VATS.

Elderly patients (>65 years):

Chronic kidney disease:

Hepatic impairment:

Anticoagulation:

Special Populations — Pregnancy, Pediatrics, Immunocompromised

— Empyema rare but more morbid; physiologic changes (elevated diaphragm, reduced FRC) lower tolerance

— Imaging: ultrasound first-line; CT chest with shielding acceptable if needed — fetal dose minimal, do not withhold for diagnosis

— Safe antibiotics: penicillins, cephalosporins, clindamycin, vancomycin, azithromycin

— Avoid: fluoroquinolones (cartilage), tetracyclines (teeth/bone), aminoglycosides (8th nerve), metronidazole controversial in 1st trimester (use clindamycin instead for anaerobes)

— Thoracentesis and chest tubes safe in pregnancy; position left lateral decubitus to avoid IVC compression

— Streptococcus pneumoniae and Staph aureus (including MRSA) most common

— Ultrasound preferred over CT to reduce radiation

— Smaller-bore pigtail catheters with intrapleural tPA highly effective (pediatric MIST-equivalent data)

— VATS early consideration; pediatric outcomes excellent with combined approach

— Vaccinate against pneumococcus and influenza after recovery

— Broaden differential: TB, Nocardia, fungal (Aspergillus, Cryptococcus), PJP with effusion

— Send AFB, fungal stain/culture, ADA, galactomannan

— Empiric broad-spectrum + early ID consult; consider antifungal coverage

— Neutropenic patient with pleural effusion — assume fungal until proven otherwise

— TB pleurisy disproportionately common; ADA >40 with lymphocytic exudate strongly suggestive

— Kaposi sarcoma can cause hemorrhagic effusion

Key distinction: A lymphocyte-predominant exudate in an HIV or recently-immigrated patient is TB until proven otherwise — start empiric 4-drug therapy while awaiting cultures; do not assume bacterial empyema.

Step 3 management: In pregnant patient, choose ceftriaxone + clindamycin as default empiric regimen.

Pregnancy:

Pediatrics:

Immunocompromised hosts (HIV, transplant, chemotherapy, biologics):

HIV-specific:

Complications and Adverse Outcomes

— Trapped lung — visceral pleural peel prevents re-expansion; requires decortication

— Bronchopleural fistula — air leak from lung into pleural space; persistent bubbling, subcutaneous emphysema; may need surgical closure or endobronchial valve

— Empyema necessitans — pus dissects through chest wall to subcutaneous tissue, classically with TB or Actinomyces

— Pleural fibrosis and restrictive lung disease — long-term FVC/TLC reduction even after successful treatment

— Pleurocutaneous fistula at chest tube site

— Pneumothorax (1–6% with US guidance, up to 30% landmark)

— Re-expansion pulmonary edema — drain no more than 1–1.5 L at one sitting, stop if cough/chest discomfort or pleural pressure < –20 cm H2O

— Bleeding, intercostal artery laceration (avoid by going over the rib, not under)

— Diaphragmatic or solid organ injury

— Chest tube malposition, kinking, or accidental removal

— Sepsis, septic shock, multi-organ failure

— Bacteremia with metastatic infection (endocarditis, septic arthritis, brain abscess)

— Hospital-acquired complications: VTE, C. difficile, deconditioning, delirium

— Persistent fever despite drainage → undrained loculation, wrong antibiotic, alternative diagnosis (PE, drug fever, abscess)

— 90-day mortality 10–20%; higher with high RAPID score

— Functional recovery often takes 3–6 months; pulmonary rehab valuable

— Recurrence rare if adequately treated; consider underlying bronchiectasis or endobronchial obstruction (malignancy) if recurrence

Board pearl: Persistent fever 72 hours after chest tube placement → repeat CT to look for undrained loculation before broadening antibiotics. Imaging beats empiric escalation.

CCS pearl: Add VTE prophylaxis with enoxaparin on admission orders — empyema patients are at high VTE risk.

Local complications:

Procedural complications:

Systemic complications:

Long-term outcomes:

Escalation of Care — ICU, Consults, Inpatient Triage

— Septic shock requiring vasopressors

— Respiratory failure requiring HFNC, NIV, or mechanical ventilation

— Massive effusion with hemodynamic instability or mediastinal shift

— Post-procedure complications (massive pneumothorax, hemothorax, re-expansion edema)

— Significant comorbidity decompensation

— Sepsis without shock, on broad antibiotics, awaiting drainage

— Recent fibrinolytic instillation requiring close monitoring

— Anticoagulated patients with chest tubes

— Pulmonology — for thoracentesis, chest tube management, fibrinolytics, bronchoscopy if endobronchial obstruction suspected

— Thoracic surgery — for VATS planning, especially in high RAPID score, loculated empyema, trapped lung

— Infectious disease — for immunocompromised, atypical pathogens, prolonged IV antibiotic planning, OPAT setup

— Interventional radiology — image-guided catheter placement when bedside not feasible

— Dental — in anaerobic empyema with poor dentition before discharge

— Nutrition — albumin <3, prolonged NPO, weight loss

— Hemodynamically stable, on appropriate antibiotics, planned next-day thoracentesis or already drained

— Failure of medical management at community hospital

— No thoracic surgery available locally

— Complex anatomy (post-pneumonectomy empyema, esophagopleural fistula)

Step 3 management: Document time-stamped consults. Early thoracic surgery consult (within 48 h of diagnosis of complicated PPE) is associated with reduced mortality even if surgery isn't ultimately performed.

CCS pearl: When advancing the clock past 48 hours without re-imaging or reassessing drainage, you will lose credit — schedule repeat CXR/US at 24 and 48 hours after each intervention.

ICU admission criteria:

Step-down/telemetry:

Consults to obtain early:

Floor admission criteria for stable simple PPE:

Transfer criteria to tertiary center:

Key Differentials — Same-Category (Pleural/Pulmonary) Causes

— CHF — bilateral, cardiomegaly, BNP elevated, responds to diuresis; if unilateral and right-sided in CHF patient, still common

— Hepatic hydrothorax — right-sided, cirrhotic, transdiaphragmatic passage of ascites

— Nephrotic syndrome — bilateral, hypoalbuminemia, proteinuria

— Atelectasis with effusion — small, postoperative, transudative

— Malignant effusion — gradual accumulation, cytology positive, often hemorrhagic; lung, breast, lymphoma top causes; recurs rapidly after drainage → consider indwelling pleural catheter or pleurodesis

— Tuberculous pleurisy — lymphocytic exudate, ADA >40, often unilateral, granulomas on pleural biopsy

— Pulmonary embolism — small, often bloody exudate, ipsilateral to infarction; consider in any unexplained effusion with pleuritic pain

— Rheumatoid pleurisy — very low glucose (<30), low pH, RF positive in fluid, chronic RA history

— Lupus pleuritis — exudate with ANA, responds to steroids

— Pancreatitis-related — left-sided, very high amylase

— Chylothorax — milky, triglycerides >110, thoracic duct injury or lymphoma

— Hemothorax — pleural Hct >50% of serum Hct; trauma, anticoagulation, malignancy

Key distinction: Lung abscess = round, thick-walled, acute angle with pleura, air-fluid level shorter on lateral than PA; empyema = lenticular, smooth inner margin, obtuse angle with chest wall, split pleura sign. Treatment differs — abscess usually responds to antibiotics alone; empyema requires drainage.

Board pearl: Very low pleural glucose (<30) narrows to empyema, RA, malignancy, TB — clinical context distinguishes.

Transudative effusions (mimics by size, not biochemistry):

Other exudative effusions:

Lung abscess vs empyema — abscess is parenchymal cavity with air-fluid level within lung; empyema is in pleural space, forms obtuse angle with chest wall; CT distinguishes reliably

Key Differentials — Other-Category Causes of Fever + Effusion

— Post-cardiac injury syndrome (Dressler) — weeks after MI or cardiac surgery, pericardial + pleural effusion, fever, elevated ESR; responds to NSAIDs/colchicine

— Aortic dissection with hemothorax — left-sided, sudden chest pain, widened mediastinum

— CHF exacerbation with concurrent pneumonia — common confounder

— Subphrenic abscess — post-surgical, sympathetic pleural effusion above, no empyema in pleural space itself; treat the abdominal source

— Esophageal perforation (Boerhaave) — left pleural effusion, high amylase, polymicrobial; surgical emergency

— Pancreatitis — left pleural effusion, very high fluid amylase, lipase elevated

— Hepatic abscess — right-sided sympathetic effusion, RUQ pain, fever

— SLE serositis — bilateral exudates, low complement, ANA positive

— Granulomatosis with polyangiitis — cavitary lung disease, glomerulonephritis, sinusitis

— Amiodarone, methotrexate, nitrofurantoin, dasatinib, bromocriptine

— Eosinophilic effusion clue

— Central line malposition causing hydrothorax

— Post-CABG effusions (usually left, weeks later, often eosinophilic)

— Post-radiation effusions

— Viral pleurisy (Coxsackie, influenza) — usually small, self-limited

— Fungal (coccidioidomycosis, histoplasmosis) — endemic regions

— Parasitic (paragonimiasis, echinococcosis) — travel history

Step 3 management: Left pleural effusion + high amylase + history of vomiting = Boerhaave until proven otherwise → CT esophagram or gastrografin study, NPO, broad antibiotics, immediate surgical consult. Missing this is a board favorite.

Key distinction: Eosinophilia in pleural fluid → think blood, air, drug, malignancy before chasing parasites.

Cardiovascular:

Gastrointestinal:

Connective tissue/autoimmune:

Drug-induced effusions:

Iatrogenic/post-procedural:

Infectious mimics not bacterial:

Secondary Prevention and Discharge Planning

— Total duration 2–6 weeks depending on response; typical empyema 4 weeks total

— Transition IV → PO when: afebrile ≥48 h, drain removed or output <50 mL/day, fluid sterile, eating, hemodynamically stable, CRP trending down

— PO options based on cultures: amoxicillin-clavulanate, moxifloxacin, levofloxacin + metronidazole, clindamycin

— OPAT (outpatient parenteral antibiotic therapy) with PICC line if prolonged IV needed — weekly CBC, BMP, drug levels (vancomycin)

— Pneumococcal: PCV20 alone OR PCV15 followed by PPSV23 in 1 year for adults ≥19 with risk factors (current 2023+ ACIP)

— Influenza annually

— COVID-19 per current schedule

— Tdap if not up to date

— Behavioral counseling + varenicline (first-line) or combination nicotine replacement (patch + lozenge)

— Document quit date, follow-up at 2–4 weeks

— Screen with AUDIT-C; if positive, brief intervention, naltrexone or acamprosate, referral

— Refer all anaerobic empyema patients for dental evaluation and periodontal treatment — recurrence prevention

— Diabetes — optimize A1c (<7–8 depending on patient factors)

— Aspiration risk — speech/swallow evaluation, head-of-bed elevation, dysphagia diet, treat reflux

— Bronchiectasis — chest physiotherapy, mucolytics, screen for underlying cause (CF, immunodeficiency)

— Continue prophylaxis through hospitalization; assess need for extended prophylaxis based on mobility

Board pearl: Pneumococcal vaccination must be addressed before discharge in every pneumonia/empyema patient — appearing on Step 3 as a preventive medicine layered question.

Step 3 management: Document medication reconciliation at discharge.

Antibiotic completion:

Vaccinations before discharge (high-yield Step 3):

Smoking cessation:

Alcohol use disorder:

Dental care:

Treat underlying conditions:

VTE prevention post-discharge:

Follow-Up, Monitoring, and Rehabilitation

— 2 weeks post-discharge: clinical assessment, repeat CBC, CMP, CRP; review symptom resolution, antibiotic tolerance, drug levels if on OPAT

— 4–6 weeks: repeat chest imaging (CXR or CT depending on baseline); residual pleural thickening expected, should be stable or improving

— 3 months: final imaging to document resolution; spirometry if dyspnea persists

— 6 months: assess functional recovery, screen for chronic pleural changes

— Residual pleural thickening common, often resolves over months

— Persistent fluid collection or new collection → re-image with CT, consider repeat drainage

— Any non-resolving infiltrate in a smoker >50 → CT chest, consider bronchoscopy to exclude obstructing malignancy as the cause of post-obstructive pneumonia/empyema

— CBC (vancomycin → cytopenias; linezolid → thrombocytopenia)

— BMP (renal function, electrolytes)

— LFTs (especially for prolonged courses)

— Drug levels (vancomycin trough)

— Line site assessment for infection, thrombosis

— Indicated if persistent dyspnea, deconditioning, or pre-existing COPD

— Improves exercise capacity, quality of life

— Incentive spirometry continued post-discharge

— Return precautions: fever, increasing dyspnea, chest pain, hemoptysis

— Adherence to full antibiotic course critical

— Smoking cessation reinforcement

— Vaccination updates

— Screen for post-ICU syndrome, depression, anxiety after prolonged hospitalization (PHQ-9, GAD-7)

Step 3 management: Bronchoscopy is indicated in any adult smoker with non-resolving infiltrate or recurrent empyema in the same lobe — endobronchial obstruction (lung cancer, foreign body) is the missed diagnosis.

Board pearl: Residual pleural thickening on 3-month imaging is expected and not a treatment failure if patient is asymptomatic.

Follow-up cadence (ambulatory Step 3 thinking):

Imaging monitoring:

OPAT monitoring (weekly):

Pulmonary rehabilitation:

Counseling content:

Functional and mental health:

Ethical, Legal, and Patient Safety Considerations

— Discuss risks (pneumothorax, bleeding, infection, organ injury, re-expansion edema, need for further procedures)

— Benefits and alternatives (continued antibiotics alone, surgery)

— Document patient understanding; use teach-back

— Emergency exception applies if patient unstable and unable to consent — document the emergency clearly

— Septic encephalopathy or delirium may impair capacity; involve surrogate decision-maker per state hierarchy

— Reassess capacity as mental status improves

— Frail elderly or end-stage disease patient with empyema — discuss palliative drainage vs surgical decortication

— Document POLST/MOLST, code status, healthcare proxy

— Palliative care consult appropriate when prognosis poor or symptoms complex

— Universal protocol: time-out, site marking (correct side!), confirmation of laterality with imaging before incision

— Wrong-site thoracostomy is a sentinel event — image must be in the room

— Hand hygiene, sterile technique to prevent secondary infection of pleural space

— Discharge with PICC line — ensure OPAT team handoff, written instructions, line care education

— Medication reconciliation — common errors: missing antibiotic, missing anticoagulant restart, missing vaccines

— Communicate with PCP within 48–72 hours of discharge; ensure follow-up appointment scheduled before discharge

— Pending culture results and final sensitivities — track and act on after discharge

— TB: notify public health, initiate contact tracing if confirmed

— Occupational exposures may trigger workers' comp documentation

— Pneumothorax from thoracentesis, malposition, hemothorax — disclose to patient and document; transparency is ethical and legal standard

Step 3 management: Always confirm TB has been excluded before discharging on prolonged antibiotics — missing TB risks community transmission and is a reportable safety event.

Informed consent for thoracentesis and chest tube:

Capacity assessment:

Goals of care:

Patient safety — procedural:

Transitions of care risks (Step 3 favorite):

Mandatory reporting and public health:

Disclosure of adverse events:

High-Yield Associations and Rapid-Fire Facts

Board pearl: When the question stem gives a numeric pleural pH, the expected next step is almost always determined by the 7.20 threshold — anchor your answer there before considering distractors.

pH <7.20 → chest tube indicated

Glucose <40, LDH >1000 → complicated PPE

Frank pus on tap → empyema, immediate drainage (skip pH)

Split pleura sign on contrast CT → empyema hallmark

Obtuse angle with chest wall → empyema; acute angle → lung abscess

Light's criteria — protein ratio >0.5, LDH ratio >0.6, LDH >⅔ ULN

MIST-2 regimen — tPA 10 mg + DNase 5 mg intrapleurally BID × 3 days

RAPID score — predicts 3-month mortality in pleural infection

Streptococcus anginosus group — most common community empyema isolate

Foul-smelling fluid → anaerobes, aspiration source

Empyema necessitans → TB or Actinomyces classic

Very low glucose (<30) → empyema, RA, malignancy, TB

ADA >40 with lymphocytic exudate → TB pleurisy

Pleural fluid amylase elevated → esophageal rupture or pancreatitis

Pleural Hct >50% serum → hemothorax

Triglycerides >110 → chylothorax

Aminoglycosides inactivated at low pH — avoid in empyema

Drain no more than 1–1.5 L at one sitting → prevents re-expansion pulmonary edema

Small-bore (10–14 Fr) catheters = large-bore (MIST-1) for outcomes

VATS before open thoracotomy when surgery indicated

Anaerobic empyema → dental consult before discharge

Pneumococcal vaccination before discharge in all CAP/empyema

Smoker with non-resolving pneumonia/empyema → bronchoscopy for malignancy

Boerhaave = left effusion + high amylase + vomiting → emergent surgery

Left-sided effusion + pancreatitis = high amylase

Right-sided effusion in cirrhotic = hepatic hydrothorax

Trapped lung → decortication

Bronchopleural fistula → persistent air leak, surgical or endobronchial valve

Board Question Stem Patterns

— 60 y/o on day 4 of ceftriaxone/azithromycin for CAP, persistent fever, new effusion on CXR

— Next step: bedside ultrasound + diagnostic thoracentesis

— Trap: "broaden antibiotics to pip-tazo"

— Pleural fluid pH 7.15, glucose 32, LDH 1400, loculated effusion on US

— Best next step: chest tube placement

— Trap: "continue antibiotics and repeat CXR in 48 h"

— Thoracentesis returns thick yellow pus

— Next step: large-bore chest tube and broad-spectrum antibiotics (do not wait for pH)

— Alcoholic with poor dentition, 3-week cough, foul-smelling sputum, right lower lobe effusion

— Organism: anaerobes + oral streptococci

— Empiric: ampicillin-sulbactam

— Loculated empyema with inadequate drainage at 48 h despite chest tube

— Next step: intrapleural tPA + DNase

— Trap: "VATS now" (only after fibrinolytic failure)

— Persistent space on imaging after 7 days of drainage and fibrinolytics, lung won't re-expand

— Next step: VATS decortication

— Left pleural effusion, severe vomiting episode, fluid amylase 4000

— Diagnosis: esophageal perforation → CT esophagram, NPO, broad antibiotics + antifungal, surgery

— Immigrant from endemic area, lymphocytic exudate, ADA 75, negative bacterial cultures

— Next step: pleural biopsy and start RIPE empirically

— Smoker with recurrent same-lobe pneumonia or empyema

— Next step: bronchoscopy for endobronchial lesion

— Recovering empyema patient ready for discharge

— Don't forget: pneumococcal + influenza vaccine, smoking cessation, dental referral if anaerobic, OPAT setup, 2-week follow-up

Step 3 management: Identifying the pattern type in the first sentence of the stem accelerates correct answer selection — these patterns recur with high frequency.

Pattern 1: The "non-resolving pneumonia"

Pattern 2: The "pH cutoff"

Pattern 3: The "frank pus"

Pattern 4: The "aspirator"

Pattern 5: The "MIST-2 setup"

Pattern 6: The "trapped lung"

Pattern 7: The "Boerhaave masquerader"

Pattern 8: The "TB pleurisy"

Pattern 9: The "malignancy hiding"

Pattern 10: The "discharge bundle"

One-Line Recap

Empyema and complicated parapneumonic effusion demand prompt thoracentesis-driven risk stratification, early chest tube drainage when pH <7.20 / glucose <40 / Gram stain positive / pus is present, broad antibiotic coverage including anaerobes, intrapleural tPA + DNase for loculated collections, and surgical referral for failure or trapped lung.

Board pearl: Mortality is driven less by antibiotic choice than by time to source control — when in doubt, drain.

Diagnosis pearl — Any pneumonia patient with persistent fever after 48–72 hours of appropriate antibiotics needs imaging and a diagnostic tap; the pH 7.20 threshold drives the drainage decision, and the split pleura sign on contrast CT confirms empyema.

Treatment pearl — Empiric therapy is ampicillin-sulbactam for community-acquired empyema (anaerobic coverage built in), or vancomycin + piperacillin-tazobactam for hospital-acquired or MRSA risk; avoid aminoglycosides (inactivated at low pleural pH), and plan 2–6 weeks of antibiotics total with IV-to-PO transition once drainage is adequate and patient is afebrile.

Procedural pearl — Small-bore image-guided catheters are equivalent to large-bore tubes for most empyemas (MIST-1); add intrapleural tPA 10 mg + DNase 5 mg BID × 3 days (MIST-2) for loculated or poorly draining collections before escalating to VATS decortication, which itself precedes open thoracotomy.

Discharge pearl — Don't leave the hospital without pneumococcal and influenza vaccination, smoking cessation counseling, dental referral in anaerobic empyema, OPAT setup with weekly labs, and 2-week clinic follow-up; in any smoker with non-resolving or recurrent empyema, bronchoscopy excludes obstructing malignancy as the underlying driver.